logo
North Chicago D187 scholarship program continues to grow; ‘They find careers which are economically sustainable'

North Chicago D187 scholarship program continues to grow; ‘They find careers which are economically sustainable'

Chicago Tribune6 days ago
As a young girl, Evalyn Alvarez spent a lot of time going places with her grandmother while her mother was at work. One of those places was the doctor's office, as her grandmother sought diabetes treatment.
Sitting there with her grandmother, Alvarez saw frustration in the woman's face sensing she did not understand everything that was happening. As Alvarez got older, and her English became fluent — Spanish is her first language — she became her grandmother's interpreter. There was a change.
'As I did that, she understood everything and she felt better,' Alvarez said. 'I saw this with other people, too. I knew if I went into healthcare, I could help people. You can really help people in the medical field.'
Now studying for the state exam to earn a certificate as a medical assistant to go to work in that field, Alvarez earned her associate's degree in May from the College of Lake County, studying to go into the healthcare profession.
Alvarez was one of 19 members of the North Chicago Community High School Class of 2023's Warhawk Lancer Scholars, providing her with tuition and other resources to complete her studies and reach the cusp of embarking on her career.
Starting with six students from the Class of 2020, the program grew to 26 scholars this year. District 187 Superintendent John Price said the scholarship is not need-based. Participants complete an application process and are selected on merit.
Along with tuition to CLC, Price said the scholarship includes fees, books, supplies, a new computer, counseling, mentoring and a $3,000 annual stipend to help with expenses they incur during the school year.
Some students complete their two-year associate's degree from CLC and matriculate to a four-year college or university, like Jasmine Nieto, who earned a business degree from Northeastern Illinois University in Chicago last spring. She plans a career in business management.
Still more of the Warhawk Lancer Scholars — Price said the ratio is approximately 2-to-1 — like Alvarez and Jose Cervantes find good, well-paying careers in healthcare, a skilled trade or dental hygiene while at CLC.
'I love that they find careers which are economically sustainable,' Price said, 'A lot of them come out of high school not knowing what they want to do. We provide counseling (during the program) to help them decide.'
Since the Warhawk Lancer program started six years ago, it has grown nearly fourfold. After awarding six in 2020, the cohorts grew to 10 in 2021, 16 in 2022, 19 in 2023, 25 in 2024 and 26 this year.
As the program grew, District 187 added another program in 2022 for graduates who want a career in early childhood education. Price said the North Chicago Public Education Foundation was started to raise money for both programs and an emergency fund. It now has an executive director and a counselor.
With 26 students heading to CLC as Warhawk Lancer Scholars this year, Price said another 24 2025 graduates are enrolling as well. Price said he wants to raise enough money through the foundation to eventually give a Warhawk Lancer Scholarship to everyone going there.
Some of the scholars enter CLC with an idea of what they want to do, while others need to explore possibilities from the array of choices at the college. Mary Kenney, the foundation's director of student success, helps them explore the opportunities.
'Some want a medical career,' Kenney said. 'I help them look at all the possibilities. Some want premed, but eventually find something else in the medical field. If someone wants a career in medicine or engineering, I counsel them to look at courses in math and science.'
Alvarez said Kenney was a big help to her. So was the Warhawk Lancer alum who became her mentor. Just as the $3,000 stipend allowed her to go to CLC without working at the same time, Kenney and her mentor helped in their own way.
'Ms. Kenney made me feel good when we talked and I asked questions,' Alvarez said. 'I was able to ask my mentor a lot of questions.'
Nieto, who is looking for a career in operations management, said she became a mentor as she transitioned from CLC to Northeastern. She wanted to help guide them as others had done the same for her.
'Some of them were first-gen like myself,' Nieto said, referring to those who are the first member of their family to go to college. 'It makes me feel like I'm helping them like others helped me.'
Starting at CLC, Nieto said she took classes required for her associate's degree. Some were business-related because she knew she wanted to be a part of the business world and pursue a four-year degree in business administration.
'I like operations management because you oversee the day-to-day operations of the business,' Nieto said. 'You solve problems and make sure everything runs smoothly.'
When Cervantes started at CLC, he knew he wanted to develop a skill that would lead to a good-paying job. He explored the welding, automotive technician and collision repair programs. He talked to teachers in all three, decided on collision repair and now works as an apprentice at a body shop.
'It makes me feel good to see a fixed car,' Cervantes said. 'When you see all that damage, you're not sure what you're going to do. You have to be patient because there are a lot of things you have to do.'
With the program seeing students through three years at CLC if needed, Price said three members of the first cohort of six completed the program, with two earning degrees and one a certificate. Of the 10 in the second group, five finished with three degrees and two earned certificates.
Of the 16 from the Class of 2022, nine finished the program with five degrees, two certificates, two transfers and two still active. From the 19 students in the Class of 2023, eight finished with four receiving degrees, three certificates, a transfer and six still active in their third year.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hippocratic AI and Sheba Medical Center Partner to Transform Patient Care with Generative AI Integration
Hippocratic AI and Sheba Medical Center Partner to Transform Patient Care with Generative AI Integration

Business Wire

time3 hours ago

  • Business Wire

Hippocratic AI and Sheba Medical Center Partner to Transform Patient Care with Generative AI Integration

PALO ALTO, Calif. & RAMAT GAN, Israel--(BUSINESS WIRE)--Hippocratic AI, the global leader and pioneer in generative AI healthcare agents, today announced a partnership with Sheba Medical Center, a global beacon of medical innovation and research ranked by Newsweek as one of the top ten hospitals in the world. The partnership brings together Hippocratic AI's leading AI agent technology and Sheba's internationally acclaimed ARC (Accelerate, Redesign, Collaborate) Innovation Center to deploy safe, effective, and scalable AI solutions that transform healthcare delivery. Additionally, Hippocratic AI will join the ARC ecosystem, which is a global network consisting of leading hospitals, researchers, and innovation organizations. This ecosystem opens the door to new potential pathways for meaningful impact with others in the network. Hippocratic AI and Sheba are collaborating to advance their shared vision of creating a future of healthcare abundance by expanding access, enhancing quality, and improving the patient experience with empathetic, clinically rigorous AI that is both safe and effective. To date, healthcare providers have used Hippocratic AI GenAI healthcare agents to complete more than 2.49 million patient calls, earning an average patient satisfaction rating of 8.95 out of 10. 'Partnering with Sheba is an important step forward in realizing our mission to deliver safe, effective, high-quality generative AI healthcare at scale,' said Munjal Shah, Co-Founder and CEO of Hippocratic AI. 'Sheba's strong reputation for clinical excellence, and its innovation ecosystem at ARC make it the perfect partner to help us deliver transformative AI tools to providers and patients worldwide.' As part of its institutional vision to redefine the future of medicine, Sheba Medical Center is helping to drive the global shift toward AI-powered healthcare. Sheba combines clinical excellence with system-wide innovation, aiming to integrate safe, effective, and compassionate AI into real-world care at scale. This partnership with Hippocratic AI is part of Sheba's broader effort to become a fully AI-enabled health system and serve as a model for integrated responsible, patient-centered innovation. At the heart of this innovation is Sheba's ARC Innovation Center, a multidisciplinary model designed to transform healthcare by uniting clinicians, entrepreneurs, and researchers. Through this partnership, Hippocratic AI will integrate its generative AI agents to support non-diagnostic, patient-facing roles into Sheba's live clinical and research environments. Initial areas of collaboration include, but are not limited to, triage and patient intake. The agents will initially launch in English, followed by Hebrew in a later phase. With Sheba Medical Center recognized as one of the leading health systems in the Middle East, it serves as a global destination for patients seeking advanced, high-quality care. Sheba receives patients from both the region, including Jordan and Egypt, and beyond, delivering trusted, personalized treatment across a broad range of specialized services. Both organizations are guided by deeply aligned missions and values. Sheba's institutional mission is to deliver world-class medical care to all, regardless of background, religion, or nationality and to lead the way in cutting-edge research, innovation, and compassionate treatment. Its values include inclusivity, humanitarianism, and global impact. These principles align with Hippocratic AI's values to Do No Harm, Patients First, and providing Equal Access for All. "AI is transforming global health, and our partnership with Hippocratic AI supports Sheba's mission to become a fully AI-powered hospital," said Prof. Eyal Zimlichman, Founder and Director of ARC, and Chief Innovation, Transformation, and AI Officer at Sheba Medical Center. "Together, we are not just piloting a technology, but reimagining the way care is delivered – building a new clinical reality where intelligent, human-aligned systems work hand-in-hand with caregivers to elevate the standard of care worldwide." About Hippocratic AI Hippocratic AI has developed a safety-focused Large Language Model (LLM) for healthcare. The company believes that a safe LLM can dramatically improve healthcare accessibility and health outcomes in the world by bringing deep healthcare expertise to every human. No other technology has the potential to have this level of global impact on health. The company was co-founded by CEO Munjal Shah, alongside a group of physicians, hospital administrators, healthcare professionals, and artificial intelligence researchers from El Camino Health, Johns Hopkins, Stanford, Microsoft, Google, and NVIDIA. Hippocratic AI has received a total of $278 million in funding and is backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, NVIDIA's NVentures, Premji Invest, SV Angel, and six health systems. For more information on Hippocratic AI, About Sheba Medical Center The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer is generating global impact through its medical care, research and healthcare transformation. Sheba's City of Health unities specialty hospitals, research and simulation centers, a virtual hospital, and ARC (Accelerate, Redesign, Collaborate), its innovation arm which connects entrepreneurs and clinicians to advance the development and implementation of new AI and tech solutions in healthcare, and accelerates the adoption of innovation both within the hospital and in health systems worldwide. Sheba is one of the top-ten hospitals in the world, having been ranked a World's Best Hospital by Newsweek for the last seven consecutive years (2019-2025). For more information, visit: or

Auna Common Shares Begin Trading on the Lima Stock Exchange to Strengthen Company's Regional Presence and Broaden Investor Access
Auna Common Shares Begin Trading on the Lima Stock Exchange to Strengthen Company's Regional Presence and Broaden Investor Access

Business Wire

time4 hours ago

  • Business Wire

Auna Common Shares Begin Trading on the Lima Stock Exchange to Strengthen Company's Regional Presence and Broaden Investor Access

LUXEMBOURG--(BUSINESS WIRE)--Auna S.A. ('Auna' or the 'Company'), a leading healthcare services provider in Latin America with operations in Mexico, Peru, and Colombia, announced that its common shares will begin trading on the Lima Stock Exchange ('BVL') today. This milestone is part of the Company's strategy to improve trading liquidity, strengthen its presence in Latin America´s capital markets, and expand its access to local and regional investors. Auna's common shares are now traded on both the New York Stock Exchange ('NYSE') and the BVL under the ticker symbol 'AUNA'. With this listing, Auna becomes the only healthcare company currently listed on the BVL. The BVL listing enhances Auna's visibility in Latin America´s capital markets and facilitates access for Peruvian and regional investors. 'This listing is a strategic step that reflects our long-term commitment to Latin America. We want to make Auna more accessible to all investors—from global, regional and local institutional investors to individual investors, shareholders and our employees — by improving liquidity and deepening awareness of our value proposition,' said Suso Zamora, Executive Chairman and President of Auna. The combined trading presence on both exchanges is intended to enhance Auna's eligibility for inclusion in local, regional and global equity indices, further expanding and diversifying its institutional investor base. Auna's participation in the BVL is expected to provide further benefits through regional integration, greater investor reach, and increased market visibility due to the regional trading market, nuam, which is present in Peru, Chile and Colombia. About Auna Auna is one of Latin America's leading healthcare platforms, with operations in Mexico, Peru, and Colombia. It prioritizes prevention and focuses on complex diseases that represent the highest healthcare spending. Its mission is to transform healthcare by delivering access to a highly integrated offering of services in low-penetration markets across Spanish-speaking Latin America. Founded in 1989, Auna has built one of the region's largest modern healthcare platforms, consisting of a horizontally integrated network of medical care centers and a vertically integrated portfolio of oncology and general health plans. As of March 31, 2025, Auna's network included 31 healthcare facilities—hospitals, ambulatory centers, and prevention and wellness centers—with a total of 2,323 beds and 1.4 million health plan members. Cautionary Statement on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often are proceeded by words such as 'believes,' 'expects,' 'may,' 'anticipates,' 'plans,' 'intends,' 'assumes,' 'will' or similar expressions. The forward-looking statements contained herein include statements about the Company's new listing of its common shares on the BVL. These expectations may or may not be realized. Some of these expectations may be based upon assumptions or judgments that prove to be incorrect. In addition, Auna's business and operations involve numerous risks and uncertainties, many of which are beyond the control of Auna, which could result in Auna's expectations not being realized or otherwise materially affect the financial condition, results of operations and cash flows of Auna. Some of the factors that could cause future results to materially differ from recent results or those projected in forward-looking statements are described in Auna's filings with the United States Securities and Exchange Commission, including its annual report on Form 20-F filed on April 10, 2025. The forward-looking statements are made only as of the date hereof, and Auna does not undertake any obligation to (and expressly disclaims any obligation to) update any forward-looking statements to reflect events or circumstances after the date such statements were made, or to reflect the occurrence of unanticipated events. In light of the risks and uncertainties described above, and the potential for variation of actual results from the assumptions on which certain of such forward-looking statements are based, investors should keep in mind that the results, events or developments disclosed in any forward-looking statement made in this document may not occur, and that actual results may vary materially from those described herein, including those described as anticipated, expected, targeted, projected or otherwise.

How did Jane Austen die? Even after two centuries, nobody knows.
How did Jane Austen die? Even after two centuries, nobody knows.

National Geographic

time5 hours ago

  • National Geographic

How did Jane Austen die? Even after two centuries, nobody knows.

This portrait of Jane Austen was created based on her sister's watercolor sketch of the novelist—the only authenticated portrait of her. 250 years after her birth, the celebrated novelist's death remains a medical mystery that generations of experts have tried to solve. Photograph by Stefano Bianchetti, Bridgeman Images When Jane Austen died on July 18, 1817, at the age of 41, she left behind only six complete novels—and one of the most vexing medical mysteries of all time. No one knows what exactly caused her death. But Austen experienced a curious assortment of symptoms late in life, ranging from recurring fevers and fatigue to stomach issues and concerns over her changing complexion. The enduring mystery has piqued the interest of scholars and armchair sleuths alike, who have proposed a variety of medical conditions to explain her death, including cancer and accidental poisoning. (Murder or madness: What really killed Edgar Allan Poe?) The act of posthumously diagnosing Austen is part of a larger cottage industry of retrospective diagnosis, the practice of applying modern medical knowledge to diagnose someone from the past. But can it shed any insight into Jane Austen's life—and solve the mystery of her death? Born on December 16, 1775, Jane Austen appears to have had a relatively healthy childhood and young adulthood. 'Jane Austen was vigorous and active until her attacks of ill health in the last year or so of her life,' says Juliette Wells, professor of literary studies at Goucher College and guest co-curator of A Lively Mind: Jane Austen at 250 at The Morgan Library & Museum. 'Until then, her letters include many mentions of enjoying dancing, often for hours at a time, as well as long country walks.' (Jane Austen never wed, but she knew how to play the marriage game.) Austen's health took a turn around the age of 40 in 1816 while she was finishing the novel Persuasion. Her symptoms, which included rheumatism and fatigue, came and went, and she reported them in a series of surviving letters. On March 23, 1817, Austen described her complexion to her niece Fanny Knight as 'black and white and every wrong colour,' and observed, 'Sickness is a dangerous indulgence at my time of life.' Two weeks later, she complained in a letter to her brother Charles of having been 'too unwell the last fortnight to write anything that was not absolutely necessary.' She was 'suffering from a bilious attack attended with a good deal of fever.' Around that same time, her niece Caroline Austen visited and noticed the 'alteration' in her aunt. 'She was very pale, and her voice was weak and low, and there was about her a general appearance of debility and suffering; but I have been told that she never had much acute pain.' 'Jane made her will in late April, several months before she died––suggesting an understanding that her condition was serious,' notes Devoney Looser, Regents' Professor of English at Arizona State University and author of Wild for Austen: A Rebellious, Subversive, and Untamed Jane. The next month, Austen and her sister Cassandra moved to Winchester, England, where the novelist sought medical care for an unknown illness. 'The treatment was not effective, and Jane died […] in Cassandra's arms,' Wells says. (A guide to Regency Bath on the anniversary of Jane Austen's birth.) 'I have lost a treasure, such a sister, such a friend as never can have been surpassed,' Cassandra wrote two days after her sister's death. 'She was the sun of my life, the gilder of every pleasure, the soother of every sorrow.' Jane Austen's surviving letters, and those of friends and family, serve as the main sources for information about her death. But those letters don't give a full picture. In the wake of Jane's death, Cassandra destroyed many of her sister's letters, likely to protect her privacy and reputation—and unwittingly opening the door to rampant speculation. Did Jane Austen have Addison's disease or lupus? What caused Jane Austen's death? One of the most prevalent theories, first proposed in 1964 by surgeon Zachary Cope, is that Austen lived with Addison's disease, a condition in which the adrenal glands can't produce hormones such as cortisol. Addison's disease causes symptoms like the fatigue and skin darkening that Austen's letters describe. But there is one problem with that theory. In 2021, emeritus consultants at London's St. Thomas' Hospital with an interest in Jane Austen lore Michael Sanders and Elizabeth Graham pointed out that Addison's disease in Austen's era was typically caused by tuberculosis. 'Jane had no chest or orthopaedic problems to suggest TB, and both her doctors, Curtis and Lyford, would have been familiar with the diagnosis,' they wrote. Instead, they proposed a different autoimmune disease, lupus, which would account for Austen's 'rheumatism, facial skin lesions, fever and marked fluctuation of these symptoms.' Did Jane Austen die of cancer? Others, including biographer Carol Shields, believe cancer was a 'very likely cause' of the novelist's death, speculating that breast cancer may have run in Austen's family. Looser agrees that cancer appears to be 'a more plausible diagnosis,' since it 'was not uncommon' in Austen's era. If Austen had cancer, the risk of it metastasizing would have been high. 'The only available cancer treatment, surgery, was very risky in Austen's day,' Looser observes. 'It relied on being able to identify and excise the tumor, at a time when surgery itself could kill, due to the risk of infection.' Other theories include Hodgkin's lymphoma. Jane Austen scholar Annette Upfal considered Austen's full medical history and concluded that the author may have suffered earlier in life than most believe, noting 'she was particularly susceptible to infection, and suffered unusually severe infective illnesses, as well as a chronic conjunctivitis that impeded her ability to write.' In 2017, the British Library raised new questions about Austen's health when it tested three pairs of glasses that may have belonged to her and found that the glasses all had different lens strengths. According to the library, a consulting optometrist examined the results and said it was possible that Austen may have developed cataracts. He also floated a theory that those cataracts were caused by 'accidental poisoning from a heavy metal such as arsenic,' which was prevalent in the 19th century. Looser considers this 'the least credible theory.' The glasses were 'found in her writing desk' but 'may or may not have been hers.' And though Austen was 'described [as] having weak eyes,' poor vision can have many causes—not just arsenic-induced cataracts. 'So you can see how this is a leap and a stretch––from desk to glasses to vision problems to arsenic poisoning,' she says. Why it's so hard to diagnose historical figures In addition to examining old letters and belongings, scholars may also leverage surviving medical casebooks and physician's notes to diagnose historical figures. But even these shouldn't be taken at face value, notes Mindy Schwartz, professor of medicine at The University of Chicago. 'What they prioritize, what they leave out––these texts show the biases of the time and the priorities that the physicians had when creating them.' It also shows the limited resources of the time. For example, physicians in Austen's era would have made a clinical diagnosis, which took into account the patient's history and a physical examination. But this probably wouldn't have yielded a definitive diagnosis because many conditions have overlapping symptoms. 'We didn't have microbiology, CAT scans, or blood work [at the time of her illness], so it would have been hard to make an accurate diagnosis,' says Schwartz. Osamu Muramoto, senior scholar at Oregon Health & Science University's Center for Ethics in Health Care, also points out, 'Human beings are evolving, microorganisms are evolving, genes are evolving. So how can we say that disease X from 200 years ago is the same disease X as today?' Even if you could posthumously diagnose historical figures, there is some debate over whether you should. 'Some people might be concerned that this is an invasion of privacy,' explains Steven Joffe, Art and Ilene Penn Professor of Medical Ethics & Health Policy and chair of the department of Medical Ethics & Health Policy at the University of Pennsylvania. 'In my opinion, those privacy considerations diminish with time.' However, he adds, ethical considerations nonetheless should factor into any retrospective diagnosis. For example, any genetic conditions have implications for the person's surviving descendants. Muramoto also points out that there's a risk in making diagnoses that carry reputational harm because they are considered taboo, such as sexually transmitted infections. At the same time, making retrospective diagnoses about historical figures can help normalize conditions that have long been stigmatized. 'Let's say you can convincingly show that Abraham Lincoln had major depression,' Joffe theorizes. 'To me, that is actually quite de-stigmatizing because it shows how somebody can have major depression and yet be one of the most influential people in American history.' Making these diagnoses can also help recontextualize the historical figure's life and work. Take 19th-century philosopher Friedrich Nietzsche, Muramoto says. 'He spent almost a decade with very, very poor health, mental illness, dementia.' Muramoto thinks tertiary syphilis is the likely diagnosis, saying it 'would explain, in my view, the paranoid tone of his later writings.' This is likely not the case for Jane Austen. 'I wouldn't say her novels reflect the state of her health,' cautions Looser. Nonetheless, she adds, when Austen's symptoms were intensifying, she was starting to write Sanditon, an unfinished novel that 'features a send up of hypochondriacs and quack medicine.' We might never know why Jane Austen died. But we do know that she could poke fun at illness, Looser says, 'even in the face of her own growing physical problems.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store